{"id":"syh2053","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors like SYH2053 work by blocking the reabsorption of glucose in the kidneys, thereby reducing blood glucose levels. This can be particularly beneficial for patients with type 2 diabetes. By reducing glucose reabsorption, SYH2053 helps to lower blood sugar levels and improve glycemic control.","oneSentence":"SYH2053 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:07.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07465263","phase":"PHASE3","title":"A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2026-03-31","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":135},{"nctId":"NCT07421297","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2026-04-01","conditions":"Non-familial Hypercholesterolemia and Mixed Hyperlipidemia","enrollment":760},{"nctId":"NCT07421232","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-12-03","conditions":"Hypercholesterolemia and Mixed Hyperlipidemia","enrollment":156},{"nctId":"NCT07421284","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2026-03-31","conditions":"Non-familial Hypercholesterolemia and Mixed Hyperlipidemia","enrollment":900},{"nctId":"NCT06229548","phase":"PHASE1","title":"A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-01-08","conditions":"Hyperlipemia","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SYH2053","genericName":"SYH2053","companyName":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","companyId":"cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SYH2053 is a medication being studied for the treatment of Hyperlipemia, Non-familial Hypercholesterolemia, Mixed Hyperlipidemia, Hypercholesterolemia and Mixed Hyperlipidemia, and Heterozygous Familial Hypercholesterolemia (HeFH). The safety, tolerability, pharmacokinetics, and pharmacodynamics of SYH2053 are being evaluated in a single ascending dose study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}